Search results for: Downs
OIS Retina@ASRS Brings Retina Leaders Together (Again) for Live Meeting in San Antonio
The live and in-person summit showcasing innovation in retina, OIS Retina@ASRS, will be held in San Antonio, Texas, on October 7, a day before the annual meeting of the American Society of Retina Specialists opens. It will be the first live OIS meeting since 2019. The conference provides a nexus for stakeholders in retina product…
Read MoreRetina ASRS 2021 Agenda
HomeRetina ASRS 2021 AgendaSpeakersPresenting CompaniesVenueCOVID PolicyConference Day AGENDA | OCTOBER 7 time reflects central standard time 7:30 – 8:30 AM Check-in & Networking Breakfast 8:30 – 8:40 AM Opening & Hot Topics in the Retina Space Presented By: Firas M. Rahhal, MD, Partner – ExSight Ventures & Retina Vitreous Associates Medical Group 8:40 – 8:55…
Read MoreDeveloping a Clear Vision for a Clinical-Stage Company with Ben Bergo
PODCAST EPISODE 291
Read MoreBuilding a Best-in-Class Company for a Best-in-Class Therapy: LENZ Therapeutics CEO Eef Schimmelpennink
PODCAST EPISODE 290
Read MoreEarning the Right to Ask for the Business with Nick Curtis of LENSAR
PODCAST EPISODE 278
Read MoreGyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA
Gyroscope Therapeutics recently raised $148 million in a Series C financing to advance the clinical development of GT005, its lead investigational gene therapy, which is being evaluated for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GT005 also received Fast Track designation from the Food and Drug Administration for the treatment of…
Read MoreBuilding Value for Pipeline Assets with Mina Sooch
PODCAST EPISODE 275
Read MoreOsmotica Will Commercialize and Supply Non-Surgical Droopy Lid Treatment via a Wholly Owned Subsidiary
Last month, the US Food and Drug Administration approved a novel ophthalmic solution to treat acquired blepharoptosis, otherwise known as “droopy lid syndrome.” The solution, Osmotica Pharmaceuticals‘ Upneeq (oxymetazoline hydrochloride 0.1%, formerly known as RVL-1201), is a first-in-class agent and the only approved drug indicated for droopy upper eyelids, which can interfere with patients’ field…
Read MoreThe Time is Nau!
PODCAST EPISODE 238 Click here to watch the video version of this podcast. Host Ehsan Sadri, MD, is joined by Jeffrey Nau, PhD, who shares insights from a career in ophthalmology that has led to his current role as the CEO of publicly traded Oyster Point Pharma. In this interview, Jeff addresses some of the…
Read MoreOrasis CEO and Chairman Share Their Strategies for Success
PODCAST EPISODE 230 Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeffry Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology…
Read MoreAs Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For
CHICAGO – As innovation in the retina space has grown over the past quarter century, so has the need for capital to finance those activities. One way innovators are meeting that need is by entering into partnerships with ex-US entities, one of many issues explored by a panel session on financing retina innovation at OIS@ASRS…
Read MoreWhy Link Between Cognition and Vision May Emerge as a Focus of Innovation
WASHINGTON – With the graying of America and a push to create age-friendly communities and health systems, ophthalmologists and innovators in the field need to better understand the interplay between low vision and cognition for the best outcomes, a panel of experts said at Prevent Blindness’ 2019 Focus on Eye Health summit. The number of…
Read More